slides · global inventory
Clinical Trial Design
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 129
Current window 1-60
Pages 3
Rows per page 60
Framework
1-60 of 129
44
The slide outlines a standard clinical trial structure with patient inclusion criteria, study arms (Part A/B), and primary/secondary endpoints.23andMe | Investor Presentation Deck | 58 slides · 23andMe
Pitch deck Investor relations 1 hit
47
The slide outlines a standard clinical trial design including patient criteria, cohort structure (Part A/B), and primary/secondary objectives.23andMe | Investor Presentation Deck | 63 slides · 23andMe
Pitch deck Investor relations 1 hit
11
The slide outlines a randomized controlled trial structure with an open-label extension.Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
13
The slide uses a process flow diagram to illustrate the clinical trial phases.Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
22
The slide uses a process flow diagram to illustrate the clinical trial structure.Aeglea BioTherapeutics | Investor Presentation Deck | 33 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Loop · Jobs To Be Done1 hit
06
The slide uses a process flow diagram to illustrate the clinical trial phases (randomization, treatment, extension).Aeglea BioTherapeutics | Results Presentation Deck | 23 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
The slide outlines a standard randomized controlled trial (RCT) design for a pharmaceutical study.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
09
Clinical trial design diagram showing study flow and patient population metrics.Alkermes | Results Presentation Deck | 26 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
31
The slide uses a flow diagram to illustrate the randomized, double-blind, placebo-controlled study structure.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
32
The slide uses a process flow diagram to illustrate the clinical trial methodology.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
26
The slide outlines a clinical trial protocol including randomization, interim analysis for accelerated approval, and primary/secondary endpoints.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
29
The slide outlines a standard clinical trial schema with a dose-finding/safety phase followed by a randomized efficacy phase.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
36
The slide outlines a clinical trial protocol involving 180 patients, stratified by condition and severity, with a 26-week duration and specific primary/secondary endpoints.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
45
Clinical trial design diagram showing a 1:1 randomization between Efgartigimod and Placebo over 36 weeks.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
06
The slide outlines a multi-stage clinical trial process including patient identification, open-label, and placebo-controlled phases.argenx SE | Results Presentation Deck | 19 slides · argenx
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
07
The slide outlines a parallel clinical trial structure for IV and SC administration of efgartigimod.argenx SE | Results Presentation Deck | 20 slides · argenx
Conference presentation Investor relations Beat · What Is1 hit
08
The slide outlines a multi-stage clinical trial process including a Go/No Go decision point.argenx SE | Results Presentation Deck | 20 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
09
The slide outlines the dosing schedule (weeks 1-4, 5-16, and beyond) and the primary objective for the trials.argenx SE | Results Presentation Deck | 20 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
10
The slide uses a process flow diagram to illustrate the clinical trial protocol.argenx SE | Results Presentation Deck | 20 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
32
Clinical trial design diagram showing patient flow from enrollment to treatment arms.AstraZeneca | Investor Day Presentation Deck | 34 slides · AstraZeneca
Conference presentation Investor relations 1 hit
10
The slide uses a standard clinical trial flow diagram (CONSORT-style).AstraZeneca | Investor Day Presentation Deck | 35 slides · AstraZeneca
Conference presentation Investor relations 1 hit
10
The slide uses a standard clinical trial flow diagram (randomization process).AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
18
The slide uses a standard clinical trial flow diagram (CONSORT-style).AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The slide uses a standard clinical trial flow diagram (randomization process).AstraZeneca | Investor Day Presentation Deck | 43 slides · AstraZeneca
Conference presentation Investor relations 1 hit
20
The diagram illustrates a randomized clinical trial flow.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & Proof1 hit
12
The slide uses a standard clinical trial flow diagram to illustrate the study protocol.ATAI | Investor Presentation Deck | 33 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
16
The slide uses a standard clinical trial flow diagram (randomization to treatment arms).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
36
Includes study design diagram and assessment schedule table.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
39
The slide outlines two distinct clinical study parts: a Single Ascending Dose (SAD) study and a crossover comparator study.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a standard clinical trial flow diagram to illustrate study arms and assessment points.Axcella Health | Results Presentation Deck | 62 slides · Axcella Therapeutics
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
32
The slide uses a structured table layout to define the clinical trial parameters.Bionomics | Investor Presentation Deck | 38 slides · Bionomics
Pitch deck Investor relations 1 hit
50
The slide uses a process flow diagram to illustrate the clinical trial methodology.Bionomics | Investor Presentation Deck | 59 slides · Bionomics
Pitch deck Investor relations 1 hit
15
Includes clinical trial design flow chart and regulatory milestones.Bionomics | IPO Presentation Deck | 38 slides · Bionomics
Pitch deck Investment bank 1 hit
34
The slide uses a structured table-like layout to present clinical trial parameters.Bionomics | IPO Presentation Deck | 38 slides · Bionomics
Pitch deck Investment bank 1 hit
100
Clinical trial design diagram showing patient flow, randomization, and treatment arms.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Product Pipeline1 hit
25
Clinical trial design diagram showing randomization of 120 patients into three arms.BioNTech | Results Presentation Deck | 43 slides · BioNTech
Conference presentation Investor relations Beat · ProductLoop · Golden Circle1 hit
23
The slide outlines a standard oncology clinical trial structure with a 3+3 dose escalation design and specific target indications for expansion.Codiak | IPO Presentation Deck | 36 slides · Codiak
Pitch deck Investment bank Beat · Roadmap1 hit
12
The slide outlines a clinical trial protocol using a sequential phase design.Context Therapeutics | Investor Presentation Deck | 25 slides · Context Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
The slide outlines a randomized controlled trial design for Myelofibrosis treatment.CTI BioPharma | Investor Presentation Deck | 24 slides · CTI BioPharma
Pitch deck Investor relations Beat · Evidence1 hit
17
The slide outlines the clinical trial methodology for a drug combination study.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
21
The slide outlines a clinical trial methodology for a Phase 1/2 study.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
22
Clinical trial design summary for REQORSA combination therapy.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
16
The slide outlines a clinical trial methodology comparing combination therapy against monotherapy continuation.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
21
The slide outlines a clinical trial methodology comparing a novel combination therapy against a standard of care control arm.Genprex | Investor Presentation Deck | 44 slides · Genprex
Pitch deck Investor relations 1 hit
19
Clinical trial design diagram showing randomization of 3,000 infants into HIL-214 and placebo groups.Hillevax | IPO Presentation Deck | 24 slides · Hillevax
Pitch deck Investment bank Beat · Impact & Next Steps1 hit
26
The slide outlines a clinical trial methodology involving healthy volunteers (HV) and patients across SAD and MAD cohorts.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
55
The diagram illustrates a multi-arm clinical trial design with dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for various indications, including combination therapy arms.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
20
Clinical trial design diagram showing randomization into three arms with specific drug regimens over a 10-week period.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
34
Includes detailed diagrams of disease pathophysiology and clinical trial design.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
23
The slide uses a hybrid layout combining a staircase diagram for Phase 1 and a structured table for Phase 2.Nuvalent | IPO Presentation Deck | 40 slides · Nuvalent
Pitch deck Investment bank Loop · Quick Win Big Bet1 hit
17
The slide outlines a randomized, double-blind, placebo-controlled, dose-ranging proof of concept study.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations 1 hit
25
The slide outlines a clinical trial protocol including induction, randomization, and primary endpoint.RenovoRx | IPO Presentation Deck | 29 slides · RenovoRx
Pitch deck Investment bank Loop · Golden Circle1 hit
21
The slide uses a flow diagram to illustrate study design and participant disposition.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
34
The slide outlines a clinical trial program involving three studies (0169, 0170, 0171) with specific eligibility criteria and endpoints for a longitudinal analysis.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
09
The slide uses a staircase diagram to represent dose escalation and a crossover design for the food effect study.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
15
The schematic illustrates a dose-escalation study with three cohorts of 10 patients each, followed by a 4-week follow-up period.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations 1 hit
08
The slide uses a staircase diagram to represent dose escalation and a crossover diagram for the food effect study.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
14
The schematic illustrates a dose escalation study with three cohorts of 10 patients each, separated by safety review committee (SRC) checkpoints.Third Harmonic Bio | IPO Presentation Deck | 24 slides · Third Harmonic Bio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
06
The slide outlines a clinical trial structure involving two parts, with crossover periods for Part 1.Xeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit